Skip to main content
PCVX
NASDAQ Life Sciences

Vaxcyte's VAX-31 Phase 1/2 Data Published in Lancet, Demonstrating Superiority to PCV20 for Key Serotypes

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$54.2
Mkt Cap
$7.812B
52W Low
$27.66
52W High
$76.61
52W Position info
96% above low
Off High info
29% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PCVX sits 96% above its 52-week low of $27.66.

Summary

Vaxcyte announced the publication of positive Phase 1/2 adult clinical trial data for its lead 31-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-31, in The Lancet Infectious Diseases. The study demonstrated VAX-31 was well-tolerated with a safety profile similar to Prevnar 20® (PCV20) and elicited robust immune responses across all 31 serotypes. Critically, the data showed superiority to PCV20 for 11 incremental serotypes unique to VAX-31 and greater immune responses for 18 of 20 serotypes common with PCV20, with seven achieving statistical significance. This publication provides significant validation and de-risking for VAX-31, reinforcing its 'best-in-class potential' and competitive advantages over existing standard-of-care vaccines. For a clinical-stage biotech, strong positive data published in a top-tier journal is a major catalyst that can significantly enhance investor confidence and the drug's commercial outlook. Investors will now focus on the upcoming topline data from the OPUS-1 pivotal noninferiority Phase 3 trial, expected in the fourth quarter of 2026, which will be crucial for supporting a Biologics License Application.

At the time of this announcement, PCVX was trading at $54.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $27.66 to $76.61. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

PCVX - Latest Insights

PCVX
Nov 04, 2026, 5:07 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $65.68
Real-time Price: $55.30 info
Change: -$10.38 (-16%) info
Market Cap: $8.82B info
PCVX
Nov 04, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $65.68
Real-time Price: $55.30 info
Change: -$10.38 (-16%) info
Market Cap: $8.82B info
PCVX
Oct 09, 2026, 4:42 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.12
Real-time Price: $55.30 info
Change: -$15.82 (-22%) info
Market Cap: $8.82B info
PCVX
Oct 08, 2026, 4:30 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $64.94
Real-time Price: $55.30 info
Change: -$9.64 (-15%) info
Market Cap: $8.82B info
PCVX
Oct 07, 2026, 6:05 AM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $66.40
Real-time Price: $55.30 info
Change: -$11.10 (-17%) info
Market Cap: $8.82B info